Roche Reports Results of Tecentriq + CT in P-III IMpassion031 Study for Patients with Early Triple-Negative Breast Cancer
Roche Reports Results of Tecentriq + CT in P-III IMpassion031 Study for Patients with Early Triple-Negative Breast Cancer
Shots:
- The P-III IMpassion031 study involves assessing of Tecentriq + CT (Abraxane, nab-paclitaxel; followed by doxorubicin and cyclophosphamide) vs PBO + CT in 333 people in a ratio (1:1) with previously untreated, early TNBC, regardless of PD-L1 expression
- Results: met its 1EPs by demonstrating a clinically meaningful improvement in pathological complete response. Patients who received the Tecentriq combination as a neoadjuvant treatment had evidence of tumor tissue detectable at the time of surgery, regardless of PD-L1 expression
- Tecentriq + nab-paclitaxel is currently approved in 70+ countries worldwide, including the US and across EU, for the treatment of adults with unresectable LA/metastatic TNBC in people whose tumors express PD-L1
Click here to read full press release/ article | Ref: Roche | Image: Roche